The Terumo Group has established key sustainability activity themes to resolve issues related to healthcare, society, and the global environment, and is working to realize a sustainable society and sustainable growth for the Terumo Group, while also …

Terumo is a global medical device company originating from Japan. We pursue reliable quality and technology to contribute to healthcare in more than 160 countries and regions around the globe. At Terumo, we reduce patients’ difficulties both mentally and physically, while delivering solutions that help solve various issues in medical settings.

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions.

Since its establishment in 1921, Terumo has continued to build trust from patients and healthcare professionals. Under the unchanging Group Mission of “Contributing to Society through Healthcare”, we provide products and services that respond …

Currently, the Terumo Group includes three companies that operate in over 160 countries and regions around the world, providing patients, a variety of medical settings, and the pharmaceutical industry with over 50,000 products and services.

Headquartered on the East Coast of the United States, in New Jersey, Terumo Medical Corporation is the central location for four divisions, notably Terumo Health Outcomes (THO), Terumo Medical Products (TMP), the Pharmaceutical Solutions Division (PSD), and Terumo Interventional Systems (TIS).

Terumo advances healthcare based on reliable quality and technology developed with deep insight of the medical environment. Through these efforts, we contribute to saving the lives of patients, reducing their difficulties, and helping them lead a better life.

National Alliance of Sickle Cell Centers and Terumo Blood and Cell Technologies Working Together to Improve Outcomes for Patients with Sickle Cell Disease. The BET on Blood for SCD collaboration aims to improve the lives of Sickle Cell Warriors by connecting healthcare providers with education about proven treatments to help manage the disease

Terumo is a constituent of the FTSE4Good Index Series and the FTSE Blossom Japan Index (as of March 31, 2022). Terumo Group’s target for reducing greenhouse gas emission in fiscal 2030 was approved to be aligned with the “1.5 degrees pathway” by …

Terumo offers devices that circulate blood in place of the heart and lungs during cardiovascular surgery in which the heart is stopped (“on pump” surgery). During open-heart surgery, the heart-lung machine temporarily takes over the pumping function of the heart.